Characteristics of allografted patients with ATL
| Patient variables . | No. of recipients by graft source type (%) . | ||||
|---|---|---|---|---|---|
| HLA-matched related bone marrow or peripheral blood (N = 154) . | HLA-mismatched related bone marrow or peripheral blood (N = 43) . | Unrelated bone marrow (N = 99) . | Unrelated cord blood (N = 90) . | P . | |
| Age range at transplantation, y | .001 | ||||
| 30 or younger | 4 (3) | 1 (2) | 2 (2) | 1 (1) | |
| 30-40 | 21 (14) | 4 (9) | 8 (8) | 3 (3) | |
| 40-50 | 56 (36) | 12 (28) | 44 (44) | 21 (23) | |
| 50-60 | 57 (37) | 22 (51) | 43 (43) | 47 (52) | |
| Older than 60 | 16 (10) | 4 (9) | 2 (2) | 18 (20) | |
| Sex | .257 | ||||
| Male | 76 (49) | 21 (49) | 60 (61) | 52 (58) | |
| Female | 78 (51) | 22 (51) | 39 (39) | 38 (42) | |
| Disease status | .001 | ||||
| Complete remission | 50 (32) | 7 (16) | 35 (35) | 26 (29) | |
| Not in complete remission | 102 (66) | 35 (81) | 52 (53) | 57 (63) | |
| Unknown | 2 (1) | 1 (2) | 12 (12) | 7 (8) | |
| Conditioning regimen | < .001 | ||||
| CY-TBI or BU-CY | 51 (33) | 6 (14) | 43 (43) | 14 (16) | |
| Purine analog–containing | 72 (47) | 23 (53) | 37 (37) | 64 (71) | |
| Others | 31 (20) | 14 (33) | 19 (19) | 12 (13) | |
| GVHD prophylaxis | < .001 | ||||
| Cyclosporine-based | 146 (95) | 11 (26) | 29 (29) | 60 (67) | |
| Tacrolimus-based | 6 (4) | 31 (72) | 68 (69) | 25 (28) | |
| Others | 2 (1) | 1 (2) | 2 (2) | 5 (6) | |
| Source of stem cells | < .001 | ||||
| Bone marrow | 46 (30) | 12 (28) | 99 (100) | - | |
| Peripheral blood | 106 (69) | 31 (72) | - | - | |
| Bone marrow + peripheral blood | 2 (1) | 0 (0) | - | - | |
| Cord blood | - | - | - | 90 (100) | |
| HLA compatibility* | |||||
| Matched | 154 (100) | - | 83 (84) | 3 (3) | < .001 |
| One-antigen mismatch | 19 (44) | 12 (12) | 29 (32) | ||
| Two-antigen mismatch | 13 (30) | 0 (0) | 57 (63) | ||
| Three-antigen mismatch | 7 (16) | 0 (0) | 1 (1) | ||
| Uncertain/missing | 4 (9) | 4 (4) | 0 (0) | ||
| Time from diagnosis to transplantation | < .001 | ||||
| 6 months or less | 92 (60) | 26 (60) | 22 (22) | 49 (54) | |
| More than 6 months | 52 (34) | 16 (37) | 75 (76) | 41 (46) | |
| Uncertain/missing | 10 (6) | 1 (2) | 2 (2) | 0 (0) | |
| Year of transplantation | < .001 | ||||
| 1995-1999 | 18 (12) | 1 (2) | 5 (5) | 0 (0) | |
| 2000-2002 | 66 (43) | 15 (35) | 26 (26) | 12 (13) | |
| 2003-2005 | 70 (45) | 27 (63) | 68 (69) | 78 (87) | |
| Follow-up of survivors† | |||||
| Median mo (range) | 40.5 (1.5-102.3) | 36.7 (8.8-85.1) | 40.2 (16.0-81.2) | 48.9 (1.6-73.5) | .847 |
| Patient variables . | No. of recipients by graft source type (%) . | ||||
|---|---|---|---|---|---|
| HLA-matched related bone marrow or peripheral blood (N = 154) . | HLA-mismatched related bone marrow or peripheral blood (N = 43) . | Unrelated bone marrow (N = 99) . | Unrelated cord blood (N = 90) . | P . | |
| Age range at transplantation, y | .001 | ||||
| 30 or younger | 4 (3) | 1 (2) | 2 (2) | 1 (1) | |
| 30-40 | 21 (14) | 4 (9) | 8 (8) | 3 (3) | |
| 40-50 | 56 (36) | 12 (28) | 44 (44) | 21 (23) | |
| 50-60 | 57 (37) | 22 (51) | 43 (43) | 47 (52) | |
| Older than 60 | 16 (10) | 4 (9) | 2 (2) | 18 (20) | |
| Sex | .257 | ||||
| Male | 76 (49) | 21 (49) | 60 (61) | 52 (58) | |
| Female | 78 (51) | 22 (51) | 39 (39) | 38 (42) | |
| Disease status | .001 | ||||
| Complete remission | 50 (32) | 7 (16) | 35 (35) | 26 (29) | |
| Not in complete remission | 102 (66) | 35 (81) | 52 (53) | 57 (63) | |
| Unknown | 2 (1) | 1 (2) | 12 (12) | 7 (8) | |
| Conditioning regimen | < .001 | ||||
| CY-TBI or BU-CY | 51 (33) | 6 (14) | 43 (43) | 14 (16) | |
| Purine analog–containing | 72 (47) | 23 (53) | 37 (37) | 64 (71) | |
| Others | 31 (20) | 14 (33) | 19 (19) | 12 (13) | |
| GVHD prophylaxis | < .001 | ||||
| Cyclosporine-based | 146 (95) | 11 (26) | 29 (29) | 60 (67) | |
| Tacrolimus-based | 6 (4) | 31 (72) | 68 (69) | 25 (28) | |
| Others | 2 (1) | 1 (2) | 2 (2) | 5 (6) | |
| Source of stem cells | < .001 | ||||
| Bone marrow | 46 (30) | 12 (28) | 99 (100) | - | |
| Peripheral blood | 106 (69) | 31 (72) | - | - | |
| Bone marrow + peripheral blood | 2 (1) | 0 (0) | - | - | |
| Cord blood | - | - | - | 90 (100) | |
| HLA compatibility* | |||||
| Matched | 154 (100) | - | 83 (84) | 3 (3) | < .001 |
| One-antigen mismatch | 19 (44) | 12 (12) | 29 (32) | ||
| Two-antigen mismatch | 13 (30) | 0 (0) | 57 (63) | ||
| Three-antigen mismatch | 7 (16) | 0 (0) | 1 (1) | ||
| Uncertain/missing | 4 (9) | 4 (4) | 0 (0) | ||
| Time from diagnosis to transplantation | < .001 | ||||
| 6 months or less | 92 (60) | 26 (60) | 22 (22) | 49 (54) | |
| More than 6 months | 52 (34) | 16 (37) | 75 (76) | 41 (46) | |
| Uncertain/missing | 10 (6) | 1 (2) | 2 (2) | 0 (0) | |
| Year of transplantation | < .001 | ||||
| 1995-1999 | 18 (12) | 1 (2) | 5 (5) | 0 (0) | |
| 2000-2002 | 66 (43) | 15 (35) | 26 (26) | 12 (13) | |
| 2003-2005 | 70 (45) | 27 (63) | 68 (69) | 78 (87) | |
| Follow-up of survivors† | |||||
| Median mo (range) | 40.5 (1.5-102.3) | 36.7 (8.8-85.1) | 40.2 (16.0-81.2) | 48.9 (1.6-73.5) | .847 |
ATL indicates adult T-cell leukemia; HLA, human leukocyte antigen; GVHD, graft-versus-host disease; CY-TBI, cyclophosphamide with total-body irradiation; BU-CY, busulfan and cyclophosphamide; purine analog–containing, conditioning regimens containing fludarabine, cladribine, or pentostatin; cyclosporine-based, cyclosporine with or without other agents; and tacrolimus-based, tacrolimus with or without other agents.
HLA compatibility was defined according to the results of serologic or low-resolution molecular typing for HLA-A, HLA-B, and HLA-DR antigens.
Data are time interval in months.